Day: March 15, 2024

BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) — Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, will report first quarter 2024 financial results on Wednesday, May 1, 2024, after the market close. The Company will hold a conference call to discuss its first quarter 2024 results and business outlook on Thursday, May 2, 2024, at 11:00 a.m. ET. Conference call access information is as follows: Conference Call:USA Toll Free Number 877-545-0523International Toll Number 973-528-0016Access Code 638190   A simultaneous webcast of the call will be available on the Company’s website at www.hosthotels.com. A replay of the call will be available Thursday, May 2, 2024, until Saturday, June 1, 2024, via the telephone details below or via webcast on the...

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”), one notifying the Company (the “MVLS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “Market Value Standard”), and the other notifying the Company (the “MVPHS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant...

Coherent’s extended C+L-band grismCoherent introduces high-efficiency grisms and transmission gratings capable of encompassing the entire extended C+L band in a single optic.PITTSBURGH, March 15, 2024 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a leader in optical communications components and subsystems, has introduced a groundbreaking family of advanced, aberration-correcting, high-efficiency grisms and transmission gratings capable of encompassing the entire extended C+L band in a single optic. These enable construction of more cost-effective, efficient, and compact network components that support more communication channels, such as wavelength selective switches (WSS) and optical channel monitors.“Both the datacom and telecom segments are experiencing a surge in network traffic driven by the adoption of...

SINGAPORE, March 15, 2024 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that it will host a Live Virtual investor Call on Thursday, March 21, 2024, with its Chief Executive Officer, Roger Hamilton, and FatBrain AI’s Chief Executive Officer, Peter Ritz. The virtual meeting will be held as a YouTube Livestream, and will include:Post-merger Growth Strategy – Road map to 100 million students goal Genius City Plan – Road map to 100 Genius Cities goal Upgraded AI Product & Partnership – Plan to $1 billion revenue goal Update on legal actions Revised 2024 Financial Guidance A Q&A to answer shareholder enquiriesTo ensure all enquiries are answered, except those related to legal proceedings that Counsel advises should...

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical trial program also showed reduction in sinus inflammation and in acute exacerbations, which frequently result in use of antibiotics XHANCE uses the proprietary Exhalation Delivery System to enable deposition of a proven steroid in target areas of inflammation deep in the nose not typically reached by standard nasal sprays Chronic sinusitis affects approximately 30 million adults in the U.S. YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved...